The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from January 03 2012 up to and including January 06 2012 the Company bought 459 own shares representing 0.00034% of the share capital of the Company, to the total value of BGN 1460 on the Bulgarian Stock Exchange. The average price per share was BGN 3.19.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that on January 06 2012 the Company bought 11 150 shares from the capital of the company Hydroizomat AD. With this deal Sopharma AD has increased its holdings in the capital of the above-mentioned company over 5%. Sopharma AD now holds 65 222 shares or 5.02% of the capital of Hydroizomat AD. The total capital of the company is 1 299 122 shares.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from January 12 2012 up to and including January 18 2012 the Company bought 1000 own shares representing 0.00076% of the share capital of the Company, to the total value of BGN 2938 on the Bulgarian Stock Exchange. The average price per share was 2.94 BGN.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from January 19 2012 up to and including January 25 2012 the Company bought 500 own shares representing 0.00038% of the share capital of the Company, to the total value of BGN 1450 on the Bulgarian Stock Exchange. The average price per share was 2.90 BGN.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
We would like to notify that for the month of January 2012 due to the bad weather conditions Sopharma AD realized decrease in sales revenues on annual basis of 17%, including 37% for the domestic market, 9% for the export markets.
In an article dated February 4, 2012 under the name “Sopharma of Bulgaria under EU investigation” the issue of New Europe claims that Sopharma is under investigation by the EU institution (name and function is not specified) onsite in Bulgaria in relation to managing to “to supply more than 70% of the medicines required by (state) hospitals and more than 50% of prescribed medicines”. We would like to draw attention to the fact that the claim of such investigation is completely unjustified and is not supported by any evidence.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from February 23 2012 up to and including February 29 2012 the Company bought 298 own shares representing 0.000226% of the share capital of the Company, to the total value of BGN 822.67 on the Bulgarian Stock Exchange. The average price per share was 2.76 BGN.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
We would like to notify that for the month of February, 2012 Sopharma AD realized growth of sales revenues of 20% compared with the same month of the previous year, including 10% decrease of domestic sales 33% growth of export sales.
From the beginning of this year sales revenues increased with 3%, including 23% decrease of domestic sales and 13 % growth of export sales.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 01 March 2012 up to and including 07 March 2012 the Company bought 200 own shares representing 0.00015% of the share capital of the Company, to the total value of 570 BGN on the Bulgarian Stock Exchange. The average price per share was 2.85 BGN.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.
The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers.
